Viatris Reports Second-Quarter 2026 Financial Results
Pharmaceutical company Viatris reported total revenues of $3.8 billion for the second quarter, a 5% increase year-over-year. The company posted a U.S. GAAP net loss of $119 million.
Viatris, a global pharmaceutical company, announced its financial results for the second quarter of 2026. Total revenues reached $3.8 billion, marking a 5% increase on a reported basis compared to the second quarter of 2025.
The company recorded a U.S. GAAP net loss of $119 million. On an operational basis, total revenues grew by 3.5% compared to the same period last year, suggesting underlying business expansion.
Adjusted EBITDA, a measure of profitability before interest, taxes, depreciation, and amortization, stood at $1.2 billion. This figure represents an 8% operational increase compared to the second quarter of 2025, indicating improved operational efficiency.
These results provide insight into Viatris's performance within the competitive pharmaceutical landscape. The reported revenue growth, coupled with an increase in adjusted EBITDA, points to positive momentum in the company's core business operations, despite the net loss.